Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.advisorBaran, Yusufen_US
dc.contributor.authorKartal Yandım, Melis-
dc.identifier.citationKartal Yandım, M. (2015). Expression levels of bioactive sphingolipid genes in newly diagnosed and drug-resistant chronic myeloid leukemia patients and their impact on the clinical progress. Unpublished doctoral dissertation, İzmir Institute of Technology, İzmir, Turkeyen_US
dc.descriptionThesis (Doctoral)--Izmir Institute of Technology, Molecular Biology and Genetics, Izmir, 2015en_US
dc.descriptionIncludes bibliographical references (leaves: 78-94)en_US
dc.descriptionText in English; Abstract: Turkish and Englishen_US
dc.descriptionxii, 94 leavesen_US
dc.description.abstractBioactive sphingolipids are a family of lipids including ceramide, glucosylceramide (GC), sphingosine-1-phosphate (S1P) and ceramide-1-phosphate (C1P) that have important functions in cellular processes including proliferation, metastasis, invasion, inflammatory response and apoptosis. Many sphingolipidregulated functions are directly related to cancer initiation, progression, and response or resistance to anti-cancer treatments. Ceramide, the central molecule of the sphingolipid metabolism, functions as a tumor-suppressor inhibiting cell division, and inducing cell differentiation, senescence and apoptosis. De novo synthesis of ceramides is regulated by ceramide synthase gene family (CERS1-6). Although ceramide is known to be a pro-apoptotic molecule, GC and S1P which are converted from ceramides by glucosylceramide synthase (GCS) and sphingosine kinase-1 (SK-1), respectively, are anti-apoptotic. Chronic myeloid leukemia is a hematological disorder arisen from the reciprocal translocation between BCR gene on chromosome 22, and ABL gene on chromosome 9, t(9;22)(q34;q11), resulting in the formation of Philadelphia (Ph) chromosome. Ph chromosome encodes BCR/ABL fusion protein having constitutively active tyrosine kinase activity. In this study, we examined the expression levels of CERS1-6, GCS, SK1, and BCR/ABL genes of 66 patients that are newly diagnosed, tyrosine kinase inhibitor (TKI)-resistant, or -sensitive. Q-PCR results showed that there were higher expression levels of apoptotic CERS1-6 in the patients TKI-treated and have shown minimum hematological response than that of the patients newly diagnosed and TKI-resistant. However, expression levels of antiapoptotic GCS and SK-1 genes were significantly higher in TKI-resistant and blastic phase patients than that of the other patients. Additionally, BCR/ABL expression levels were higher in newly diagnosed and TKIresistant patients.en_US
dc.publisherIzmir Institute of Technologyen_US
dc.subjectCancer patientsen_US
dc.subjectHematologic diseasesen_US
dc.titleExpression levels of bioactive sphingolipid genes in newly diagnosed and drug-resistant chronic myeloid leukemia patients and their impact on the clinical progressen_US
dc.title.alternativeYeni tanı ve dirençli kronik miyeloid lösemi hastalarında biyoaktif sfingolipid genlerinin ekspresyon düzeyleri ve klinik seyire etkilerien_US
dc.typeDoctoral Thesisen_US
dc.institutionauthorKartal Yandım, Melis-
dc.departmentThesis (Doctoral)--İzmir Institute of Technology, Molecular Biology and Geneticsen_US
item.fulltextWith Fulltext-
item.openairetypeDoctoral Thesis-
Appears in Collections:Phd Degree / Doktora
Files in This Item:
File Description SizeFormat 
T001308.pdfDoctoralThesis4.22 MBAdobe PDFThumbnail
Show simple item record

CORE Recommender

Page view(s)

checked on Jun 5, 2023


checked on Jun 5, 2023

Google ScholarTM


Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.